Suzanne E Davis
Overview
Explore the profile of Suzanne E Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
1600
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neelapu S, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke F, et al.
Nat Rev Clin Oncol
. 2017 Sep;
15(1):47-62.
PMID: 28925994
Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce...
2.
Tang C, Sherman S, Price M, Weng J, Davis S, Hong D, et al.
Clin Cancer Res
. 2017 Mar;
23(6):1414-1421.
PMID: 28275168
Slow-accruing clinical trials delay the translation of basic biomedical research, contribute to increasing health care costs, and may prohibit trials from reaching their original goals. We analyzed a prospectively maintained...
3.
Tang C, Hess K, Sanders D, Davis S, Buzdar A, Kurzrock R, et al.
Clin Cancer Res
. 2016 Nov;
23(6):1407-1413.
PMID: 27852698
Information on processes for trials assessing investigational therapeutics is sparse. We assessed the trial development processes within the Department of Investigational Cancer Therapeutics (ICT) at MD Anderson Cancer Center (Houston,...
4.
Tam A, Lim H, Wistuba I, Tamrazi A, Kuo M, Ziv E, et al.
J Vasc Interv Radiol
. 2015 Dec;
27(1):8-19.
PMID: 26626860
No abstract available.
5.
Blumenschein Jr G, Saintigny P, Liu S, Kim E, Tsao A, Herbst R, et al.
Clin Cancer Res
. 2013 Oct;
19(24):6967-75.
PMID: 24166906
Purpose: To report the clinical efficacy of sorafenib and to evaluate biomarkers associated with sorafenib clinical benefit in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) program....
6.
Tsao A, Liu S, Lee J, Alden C, Blumenschein Jr G, Herbst R, et al.
J Thorac Oncol
. 2013 Apr;
8(5):658-61.
PMID: 23584298
Background: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory non-small-cell lung cancer (NSCLC) patients into four...
7.
Tsao A, Liu S, Lee J, Alden C, Blumenschein G, Herbst R, et al.
J Thorac Oncol
. 2012 Oct;
7(11):1645-52.
PMID: 23059780
Background: Treating elderly non-small-cell lung cancer (NSCLC) patients in the salvage setting is challenging because of concerns of intolerance to therapy. Here we report outcomes (survival and toxicity) of elderly...
8.
Kim E, Herbst R, Wistuba I, Lee J, Blumenschein Jr G, Tsao A, et al.
Cancer Discov
. 2012 May;
1(1):44-53.
PMID: 22586319
Unlabelled: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomized study in 255 pretreated lung cancer patients. Following...
9.
Wistuba I, Gelovani J, Jacoby J, Davis S, Herbst R
Nat Rev Clin Oncol
. 2011 Mar;
8(3):135-41.
PMID: 21364686
Many experts agree that personalized cancer medicine, defined here as treatment based on the molecular characteristics of a tumor from an individual patient, has great potential in the therapy of...
10.
Puvabanditsin S, Garrow E, Weerasethsiri R, Patel N, Davis S, Azuma M
Hong Kong Med J
. 2008 Oct;
14(5):411-3.
PMID: 18840917
Central venous catheters are widely used in children, particularly in very-low-birth-weight infants in whom long-term access to the venous system is required. This may be achieved by using peripherally inserted...